TVTX Travere Therapeutics, Inc.
Price Chart
Executive Summary
Travere Therapeutics entered into a license and collaboration agreement with EverestMedicines for exclusive rights to develop and commercialize civorebrutinib (BTK inhibitor) outside China and Southeast Asia. Travere will pay $112.5M upfront with up to ~$1.03B in milestones and tiered royalties. The deal expands Travere's pipeline in immune-mediated kidney diseases but carries development and cash burn risks. A recent executive departure (8-K filed May 21) adds uncertainty around management continuity.
Key Financial Metrics
Actionable Insight
Monitor the HSR clearance and any updates on development timeline for civorebrutinib. The recent executive departure (May 21) could indicate management transition; watch for further changes or clarity on leadership. The deal adds pipeline value but increases near-term cash burn.
Key Facts
- Exclusive license for civorebrutinib (EVER001), a BTK inhibitor, for all therapeutic uses outside China and parts of Southeast Asia
- Upfront payment of $112.5 million to Everest
- Potential milestones up to approximately $1.03 billion across up to five indications
- Tiered royalties from high single-digit to double-digit percentages on net sales
- Travere responsible for development and commercialization in the Territory; cost-sharing on global trials
- Agreement subject to HSR waiting period and other customary conditions
- Prior 8-K (May 21, 2026) disclosed an executive departure and equity plan amendment
Financial Impact
Upfront payment of $112.5 million, plus up to $1.03 billion in contingent milestones and tiered royalties
Risk Factors
- Cash burn from $112.5M upfront and ongoing development costs
- Clinical and regulatory risks for civorebrutinib (still in development)
- Potential management disruption from recent executive departure
- Competition in BTK inhibitor space
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-252474 |
| Document: 0001193125-26-252474-index-headers.html | 0001193125-26-252474 |
| Document: 0001193125-26-252474-index.html | 0001193125-26-252474 |
| Document: 0001193125-26-252474.txt | 0001193125-26-252474 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
144
| $51.80 awaiting T+1 | awaiting T+1 | — | $52.04 (+0.46%) |
|
Jun 2, 2026
12d ago
|
8-K
| $42.96 $45.20 | ▲ +5.21% | ▲ +5.94% | $52.04 (+21.14%) |
|
May 15, 2026
4w ago
|
144
| $42.59 $42.89 | ▲ +0.70% | ▲ +0.77% | $52.04 (+22.19%) |
|
May 5, 2026
5w ago
|
144
| $44.76 $42.66 | ▼ −4.69% | ▼ −4.36% | $52.04 (+16.26%) |
|
May 4, 2026
5w ago
|
144
| $44.80 $44.80 | · 0.00% | ▼ −1.38% | $52.04 (+16.16%) |
|
May 1, 2026
6w ago
|
Insider Cluster
| $44.12 $44.91 | ▼ −1.79% | ▼ −2.13% | $52.04 (−17.95%) |
|
Apr 15, 2026
8w ago
|
144
| $40.95 $39.54 | ▼ −3.44% | ▼ −3.70% | $52.04 (+27.08%) |
|
Apr 15, 2026
8w ago
|
Insider Cluster
| $40.95 $39.54 | ▲ +3.44% | ▲ +3.70% | $52.04 (−27.08%) |
|
Apr 14, 2026
8w ago
|
8-K
| $42.13 $40.95 | ▼ −2.80% | ▼ −3.58% | $52.04 (+23.52%) |
|
Apr 14, 2026
8w ago
|
Insider Cluster
| $42.13 $40.95 | ▲ +2.80% | ▲ +3.58% | $52.04 (−23.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access